1.200USD-5.51%Mkt Cap: 74.61M USDP/E: —Last update: 2026-06-01
Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors. The company's lead product candidate is the PLN-…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap74.61M USD
Enterprise Value-63.47M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-149.34M USD
Revenue/Share—
Last Price1.200 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees49
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.23
PEG—
EV/EBITDA0.57
EV/Revenue—
P/S—
P/B0.43
EPS (TTM)-1.83
EPS (Forward)-1.03
52W Range
1.09013% of range1.950
52W High1.950 USD
52W Low1.090 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-82.42%
ROA-66.31%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-128.34M USD
CapEx (TTM)374.00K USD
FCF Margin—
FCF Yield-82.84%
Net Debt-142.11M USD
Net Debt/EBITDA1.28
Balance Sheet
Debt/Equity0.16
Current Ratio16.89
Quick Ratio16.50
Book Value/Sh2.949 USD
Cash/Share2.760 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating3.0 (Hold)
Target (Mean)2.667 USD
Target Range2.000 USD – 3.000 USD
# Analysts3
Ownership
Shares Out.61.92M
Float60.23M
Insiders2.35%
Institutions81.95%
Short Interest
Short Ratio7.3d
Short % Float5.69%
Short % Out.5.56%
Shares Short3.44M
Short (prev mo.)3.64M
Technical
SMA 501.250 (-4.0%)
SMA 2001.388 (-13.5%)
Beta—
S&P 52W Chg27.70%
Avg Vol (30d)511.35K
Avg Vol (10d)556.90K
Technical Indicators
RSI (14)57.4
MACD-0.0022
MACD Signal-0.0140
MACD Hist.+0.0118
BB Upper1.271 USD
BB Middle1.205 USD
BB Lower1.139 USD
BB Width10.97%
ATR (14)0.0528 USD
Vol Ratio (20d)0.48x